Bioconjugate Chemistry · 2021 · 19 citations · 43 references
PharmacyPharmaceuticsPharmacologyDrug DeliveryMolecular ImagingTargeted Drug DeliveryCancer Drug DeliveryControlled Release MechanismsPh-responsive Drug DeliveryProstate Cancer ImagingProtein TargetingCargo Release KineticsIntracellular Cargo ReleasePayload Release KineticsPh-responsive LinkersPh-responsive Release SystemsPh-triggered Drug Release KineticsProstate-specific Membrane Antigen TargetingRelease Kinetics
The tunable nature of phosphoramidate linkers enables broad applicability as pH-triggered controlled-release platforms, particularly in the context of antibody- and small-molecule-drug conjugates (ADCs and SMDCs), where there remains a need for new linker technology. Herein, we explored in-depth the release of turn-on fluorogenic payloads from a homoserinyl-based phosphoramidate acid-cleavable linker. Kinetics of payload release from the scaffold was observed in buffers representing the pH conditions of systemic circulation, early and late endosomes, and lysosomes. It was found that payload release takes place in two key consecutive steps: (1) P-N bond hydrolysis and (2) spacer immolation. These two steps were found to follow pseudo-first-order kinetics and had opposite dependencies on pH. P-N bond hydrolysis increased with decreasing pH, while spacer immolation was most rapid at physiological pH. Despite the contrasting release kinetics of these two steps, maximal payload release was observed at the mildly acidic pH (5.0-5.5), while minimal payload release occurred at physiological pH. We integrated this phosphoramidate-payload linker system into a PSMA-targeted fluorescent turn-on probe to study the intracellular trafficking and release of a fluorescent payload in PSMA-expressing prostate cancer cells. Results showed excellent turn-on and accumulation of the coumarin payload in the late endosomal and lysosomal compartments of these cells. The release properties of this linker mark it as an attractive alternative in the modular design of ADCs and SMDCs, which demand selective intracellular payload release triggered by the pH changes that accompany intracellular trafficking.
43
Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2021 · 17.4K citations · Full text
In vivo cancer targeting and imaging with semiconductor quantum dots
Xiaohu Gao, Yuanyuan Cui, Richard M. Levenson et al. · Nature Biotechnology · 2004 · 4.7K citations
Assessment of <sup>68</sup>Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer
Wolfgang P. Fendler, Jérémie Calais, Matthias Eiber et al. · JAMA Oncology · 2019 · 787 citations · Full text
Medicine, Nuclear Medicine, Oncology +17
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.
Ron Israeli, C. Thomas Powell, William R. Fair et al. · PubMed · 1993 · 532 citations